Previous 10 | Next 10 |
Fourth quarter net sales of $21.2 million, gross margin of 61.0%, and net income of $0.1 million. Full year net sales of $83.6 million, up 16% from the prior year, gross margin of 60.8%, net loss of only $4.9 million, positive Adjusted EBITDA of $1.9 million and positive operating cash flows. ...
Klepierre (KLPEF) is expected to report for Q4 2023 comScore Inc. (SCOR) is expected to report $0.8 for Q4 2023 Universal Stainless & Alloy Products Inc. (USAP) is expected to report for Q4 2023 FAT Brands Inc. (FAT) is expected to report $-1.55 for Q4 2023 Jet.AI Inc. (JTAI) ...
ChromaDex Corp. (NASDAQ:CDXC) (“the Company”), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, March 6, 2024 at 4:30 p.m. ET to discuss its financial results for the fourth quarter, which ended December 31, 2023. ...
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD + ) and healthy aging research, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Brianna Gerber, will be participating in the Lytham Partners 2024 Investor ...
2024-01-23 19:28:50 ET Summary Nutraceuticals and supplements industry is gaining traction due to increasing demand for products that promote well-being. ChromaDex Corporation offers an interesting technology and product, Niagen, which boosts NAD+ levels in the body. ChromaDex...
Tru Niagen is now available to US troops through an exclusive Military program ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD + ) and healthy aging research, is proud to announce its inaugural initiative to support the US Military. ...
Neurohacker Collective and ChromaDex Partner to Optimize Cellular Health with the Debut of Qualia NAD+ PR Newswire Qualia NAD+, Featuring ChromaDex's Patented Nicotinamide Riboside (NR) Ingredient, Niagen, Well Positioned To Become Category Leader In NAD+ Supplementation. ...
Building on a growing body of research showcasing NR as a potential therapeutic strategy for PD, this is the first clinical study to showcase the safety, tolerability, and beneficial metabolic effects of high-dose NR at 3,000 mg per day ChromaDex Corp. (NASDAQ:CDXC), a global author...
This is the longest Niagen NR clinical trial to date spanning two years and showcases that long-term Niagen NR is safe and well tolerated ChromaDex Corp. (NASDAQ:CDXC), one of the global authorities on Nicotinamide Adenine Dinucleotide (NAD + ) and healthy aging research, shares...
ChromaDex Corporation (NASDAQ: CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) and healthy aging research, announced today that they will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series to discuss its latest investor p...
News, Short Squeeze, Breakout and More Instantly...
ChromaDex Corporation Company Name:
CDXC Stock Symbol:
NASDAQ Market:
ChromaDex Corporation Website:
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD + ) research with a focus on healthy aging, announced that it will hold a conference call on Wednesday, August 7, 2024 at 4:30 p.m. ET to discuss its financial results for the second quarter, which...
Results from the at-home test kit are available to HCPs and their patients through 1health ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, launches the Niagen+ NAD+ Test Kit *, now available ...
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD + ) research with a focus on healthy aging, announces the appointment of Carlos Lopez as Senior Vice President, General Counsel. Mr. Lopez will oversee the organization's legal function, includ...